Looking back on another virus battle: U-M’s role in polio history

Originally published May 2020; updated November 2025 and October 2026

Ask someone in their 70s or older, and they’ll probably remember the fear that gripped the United States in the summers of their childhood, as outbreaks of a deadly virus cropped up across the country.

Their parents may have kept them home, to protect them from getting infected at public swimming pools, movie theaters, birthday parties, camps or playgrounds.

The reason? Polio, a virus that attacked the nerves of thousands of children, teens and adults each year. Over the first half of the 20th century, it caused permanent disability in hundreds of thousands of them, and snuffed out the lives of thousands of people each year by paralyzing the muscles crucial for breathing.

Major polio outbreaks started appearing in the U.S. around the turn of the 20^th century, and one of them in the 1920s left future president Franklin D. Roosevelt unable to stand on his own. 

By the end of World War II, full-scale epidemics happened almost yearly. Tens of thousands of survivors are still alive, but many face lasting effects called post-polio syndrome.

Except for them, polio is now part of medical history in this country. No one has caught polio in the community in the U.S. since 1979, thanks to near-universal vaccination. But recent declines in polio vaccination rates in U.S. kindergarten students have raised concern.

Worldwide, public health partnerships have mounted vaccination campaigns that have reduced cases by 99.9% since 1988 and aim to end polio cases completely.

Ironically, the children who received that first polio vaccine, and got their summers back, later became the older adults who faced the highest risk from COVID-19. 

Once again, they had to shelter at home to avoid a virus, until a vaccine became available in early 2021 to protect them. Now, they need to get vaccinated against it twice annually to be best protected.

The University of Michigan played a special role in the fight against polio for many decades, from the treatment of its effects to the massive clinical trial that led to the first approved vaccine.

Here are some highlights from that history, as part of Michigan Medicine’s ongoing celebration of its medical heritage:

1915

U-M surgeon Charles Washburne, M.D., reported on poliomyelitis in the university’s medical journal. He wrote that even though Michigan hadn’t had outbreaks of the size seen in other states, half of the patients with ‘deformities’ referred for care at U-M’s hospital were because of the disease, also known as infantile paralysis.

Those patients came to U-M thanks to a state law passed in 1913, which allowed for children of needy parents to be sent to U-M’s hospital for treatment of any sickness at state expense. Washburne reported on successes in treating the lingering effects through surgery, massage and exercise. He noted that scientists elsewhere had made progress in isolating the cause of the disease and understanding how it was transmitted, and expressed hope for a vaccine “in the near future.”

He also called on states and Congress to pay as much attention to preventing contagious diseases in humans as they did to infections that killed livestock.

Though cities and counties had tried to prevent the growth of outbreaks, he wrote, “The stamping out of a disease is a long process, requiring time, money and authority over large areas. The state of Michigan must know by this time the treacherous nature of this disease, that it robs the state of human wealth, that its very magnitude requires the full state and national power to make its suppression a success.”

The next year, Michigan and the rest of the nation experienced a major surge in polio cases.

1928

James L. Wilson, M.D., the future chair of pediatrics at U-M, was a young pediatrics resident at Boston Children’s Hospital. A team from Harvard University’s nearby School of Public Health had been developing a tank-like device designed to take over for the failing muscles that kept polio patients breathing. 

Equipped with a continuous power supply and accurate gauges to keep tabs on the negative pressure inside the tank and the breathing of the patient, it was ready for its first test when an 8-year-old girl was admitted to the hospital.

The team wheeled the “tank respirator” over to the hospital, and the girl survived nearly five days before dying of a second infection. Wilson’s mentors published the result in the Journal of the American Medical Association in May 1929, and he worked for years to improve and document the use of the experimental life-support technology.

A quote from his 1932 paper on lung failure in polio patients echoes down to the time of COVID-19: “Of all the experiences that the physician must undergo, none can be more distressing than to watch respiratory paralysis in a child ill with poliomyelitis — to watch him as he becomes more and more dyspneic, using with increasing vigor every available accessory muscle of neck, shoulder and chin, silent wasting no breath for speech, wide-eyed and frightened, conscious almost to the last breath.”

In 1941, just as Wilson’s Harvard mentor Charles McKhann joined the faculty of the University of Michigan, Wilson reported the results from 500 patients treated in what became known as the “iron lung”. Eighty percent of them, he wrote, regained the ability to breathe on their own in a few weeks. Wilson became chair of pediatrics at U-M in 1944, a position he held until 1967.

1936

With dozens of young polio patients in the care of U-M teams, a new physical therapy area, complete with hot tubs and a swimming pool, is opened in the lower level of the main University Hospital to expand the options for helping patients regain the use of their limbs. It was funded by the trust created by Horace and Mary Rackham, longtime benefactors of U-M.  

Donations from the community, raised through the “President’s Ball” held annually since 1934 on Roosevelt’s birthday, helped support care and recreation for patients. 

The National Foundation for Infantile Paralysis, launched in 1938 to unify the national fundraising effort, soon became known as the March of Dimes, and community members from Girl Scouts to Kiwanis Club members worked to collect funds to help the U-M hospital and the national campaign. March of Dimes funding supported many research and education efforts around the country.

1941 

The brand-new U-M School of Public Health, recently launched as an academic unit in its own right rather than a branch of the medical and graduate schools, receives a grant from the National Foundation for Infantile Paralysis to study the polio virus. Thomas Francis, Jr., M.D., the chair of the Epidemiology department, led the work. He also worked on an influenza vaccine with a team that included a young scientist named Jonas Salk. 

Having learned about vaccine development during his time at U-M, Salk led the development of a polio vaccine at the University of Pittsburgh.

The urgency of a search for a polio vaccine grew through the 1940s and 50s, as the number of cases nationwide grew sharply.

1952

As severe outbreaks of polio nationwide left more and more young people needing “iron lungs” and other advanced care, U-M opened the nation’s third Poliomyelitis Respirator Center. 

Funded by the March of Dimes, and overseen by David G. Dickinson, M.D. it includes eight beds in University Hospital, adding to the beds used for acute care of children and adults with polio infectious. It was later expanded to 20 beds.

In addition to iron lungs, which Wilson and Dickinson felt patients should be weaned off of as soon as possible with the use of other devices, the center offered chest respirators other devices.

Polio patients also could receive customized braces and orthotics made in the hospital's own shops, to help them stand and walk despite weakened leg muscles, and use their arms. 

The specially trained staff needed to tend to the patients and equipment helped give rise to the concept of intensive care for critically ill patients. That model, where special expertise and advanced life-support technology combine, is still in effect in modern ICUs.

1954

Francis is appointed to lead a new Poliomyelitis Vaccine Evaluation Center, and conduct a national clinical trial of the vaccine developed by his former mentee Salk.

Funded by the “a million dollars’ worth of dimes” donated to the March of Dimes, it enrolled nearly 1.8 million children between the ages of six and nine – those born in the immediate post-World War II years. 

Francis designed the study for robust scientific results: Some children were selected at random to receive a placebo, and some children received no injection.

All the children were dubbed "Polio Pioneers."

The researchers were kept from knowing the results until the trial had ended and the data were analyzed by a U-M team from the Institute for Social Research and the Tabulation Service, a forerunner of today's Information Technology teams. 

1955

As Francis declared from the stage of the Rackham Amphitheater on April 12, 1955, the vaccine proved “up to 80-90 percent effective in preventing paralytic polio.”

The news soon spread around the world.

A few weeks later, the first doses of the vaccine arrived in Ann Arbor, and schoolchildren were among the first outside the clinical trial to receive the newly approved inoculation.

Within a few years, polio was all but eradicated in the United States.

The Salk vaccine, which uses an inactivated form of the virus, soon had a rival: the weakened-virus vaccine named for inventor Dr. Albert Sabin and delivered orally, rather than by injection. 

For some time, the Sabin vaccine became more standard in the United States, but by the 1980s the Salk form was mostly used in the U.S. and other developed nations. 

In the developing world, where efforts to eradicate polio have made great strides in recent decades, the oral Sabin-style vaccine is more often used because it is stable at higher temperatures. However, under rare circumstances, the weakened virus can reactivate, causing polio cases and clusters. 

But for years after the Salk vaccine became available, polio patients infected before they could be vaccinated continued to need treatment from teams at the "Old Main" University Hospital just blocks away from the Rackham Amphitheater where the vaccine announcement had been made. 

But Wilson and Dickinson published a paper in a top medical journal just two months after the vaccine announcement that spread hope of another kind: hope for those confined to iron lungs, that they could one day breathe and move on their own again. In it, they described how they and their teams had helped all but 2 of the 100 polio patients who had been placed in U-M iron lungs in the last four years gradually leave them completely. The other two only needed them for a few hours a day.

1983

For those who had been infected before the vaccines became available, the story wasn't over.

The lasting effects of polio on those who had caught it before the vaccine were becoming more and more apparent, as they entered middle age. Even people who had not had serious polio effects during their initial infections, or had received extensive therapy to regain muscle control, found themselves developing weakness in their muscles and other symptoms.

The condition has a name: post-polio syndrome.

U-M physical medicine and rehabilitation experts, led by Frederick M. Maynard, M.D., launched a Post-Polio Clinic that continues today. It helps patients with muscle and joint symptoms erupting decades after their initial experience with the infection.

One patient, Allison "Sunny" Roller, joined the clinic team and helped Maynard write manuals for care of post-polio syndrome. 

Their work gave rise to an organization focused on the condition: Post-Polio Health International. The organization funded multiple studies at U-M, and now helps clinicians, patients, families and scientists connect with care, support and research opportunities and findings worldwide.  

2018

With polio outbreaks in the Middle East and North Africa, U-M School of Public Health researchers used advanced wastewater monitoring techniques to look for trace amounts of genetic material from the virus to track spread.

2020

U-M researchers who study RNA viruses identified key mutations in the poliovirus isolated from individuals in Bangladesh who had received the oral (Sabin) vaccine and developed vaccine-derived polio. The findings also showed that while the virus had "reawakened" in these individuals, the mutations were not sufficient to allow it to spread to others. 

2025

A team of researchers in U-M Susan B. Meister Child Health Evaluation and Research Center studied vaccination rates among Michigan children over time and showed a decline in polio vaccination, and rates of other vaccines, especially during the COVID-19 pandemic. 

Meanwhile, the School of Public Health commemorated the 70th anniversary of the announcement of the Salk vaccine trial, looking back but also contemplating the current state of trust in vaccination.